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Double-blind, placebo-controlled pilot trial of
L-Leucine-enriched amino-acid mixtures on body composition
and physical performance in men and women aged 65–75 years
T Ispoglou1, H White1, T Preston2, S McElhone, J McKenna1 and K Hind1
BACKGROUND/OBJECTIVES: Adequate protein intake is essential to retaining muscle and maintaining physical function, especially
in the elderly, and L-Leucine has received attention as an essential amino acid (EAA) that enhances protein retention. The study’s
aim was to compare the efficacy of EAA mixtures on lean tissue mass (LTM) and functional performance (FP) in a healthy elderly
population.
SUBJECTS/METHODS: Thirty-six subjects (65–75 years) volunteered to receive capsules with EAAs (Groups A and B containing 20%
and 40% L-Leucine, respectively) or placebo (lactose containing 0% L-Leucine, Group C) for 12 weeks. The daily amount ranged
from 11 to 21 g (0.21 g/ kg/day) and was taken in two equal dosages alongside food, morning and evening. Main outcomes
measured before and after intervention were LTM and FP (30-s arm-curl test; 30-s chair-stand test (30-CST); 6-min walk test (6-WT);
and handgrip strength). Secondary outcomes included dietary intakes and physical activity.
RESULTS: Twenty-five subjects (11 male and 14 female) completed the study (Group A, n= 8; Group B, n= 8; Group C, n= 9). Gains
associated with medium effect sizes were noted in LTM (Group B, 1.1 ± 1.1%, P= 0.003) and FP (Group A in 30-CST (11.0 ± 11.5%,
P= 0.02) and 6-WT (8.8 ± 10.0%, P= 0.02); Group B in 6-WT (5.8 ± 6.6%, P= 0.03) and a trend in 30-CST (13.2 ± 16.0, P= 0.06)).
Significant differences between groups were not observed in secondary outcomes.
CONCLUSIONS: Twice-daily supplementation of EAAs containing 20% or 40% L-Leucine improved aspects of functional status and
at the higher level improved LTM. Further work to establish change in a larger sample and palatable supplemental format is now
required.
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INTRODUCTION
Sarcopenia is a complex and multifactorial syndrome associated
with significant clinical, social and economic consequences. With
an ageing population, age-related sarcopenia has increased, and
estimated prevalence rates are 13% in 60- to 70-year-old people
and up to 50% in people aged 80 years and over.1,2 Although
there is no consensus for the definition of sarcopenia, the
European Working Group on Sarcopenia in Older People
(EWGSOP) has based the diagnostic criteria on the presence of
low muscle mass, together with either low muscle strength or low
physical performance.3 Maintaining muscle mass and physical
function is fundamental to promoting health and independence
with age. It has particular relevance for the prevention of falls,
fracture and disability. However, the identification of effective
treatments for age-related sarcopenia represents an ongoing
challenge.
Some of the most promising interventions have been
nutritionally based.4,5 Adequate protein intake is considered
essential, and reports suggest that the current recommended
daily allowance of 0.8 g/ kg/day is insufficient for the general
population.6,7 Instead, prophylactic amounts of 1.0–1.6 g/ kg/d
and a larger proportion of high-quality protein in a meal (25–30 g)
rather than simply increasing general total protein intake are
proposed to meet the increased requirements of older people and
to prevent sarcopenia.8–10 Conversely, protein intakes decrease
with age owing to changes in taste, difficulties in chewing,
swallowing and age-related anorexia,11,12 presenting practical
challenges for achievement of higher intakes.
Research to determine the quantities of proteins and amino
acids (AAs) required for older people with existing sarcopenia or
those ‘at risk’ is a priority,3 as is their formulation, palatability and
delivery. The AA L-Leucine (leucine) has shown promise to date,
and it is associated with enhanced postprandial protein
retention.13 Leucine induces an upregulation of mRNA translation,
an increase in muscle protein synthesis (PS) and accretion and it
can reverse the age-related blunted response of muscle PS.14,15
Studies in humans have shown that muscle PS in the elderly is
superior when increasing the leucine content in a standard
mixture of essential amino acids (EAAs).16 Taking also into account
that with increasing age there is an uncoupling of the mechanism
that regulates protein balance and consequently a reduced ability
to use dietary protein for muscle synthesis,17 it is probable that
this is mediated through a mechanism involving leucine.
Longitudinal nutrition intervention studies, exploring the
effectiveness of essential EAAs, leucine and EAAs enriched with
leucine, have presented conflicting findings.18–20 The daily
ingestion of 15 g of a standard mixture of EAAs (20% leucine)
over a period of 3 months improved lean body mass in older
sedentary women18 in contrast to a daily intervention of 7.5 g,
which had no effect on lean mass.19 However, neither intervention
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resulted in increases in strength. Although studies have demon-
strated the potential for leucine as a pharmaco-nutritional
prophylaxis against age-related sarcopenia,21–25 the optimal
amount and composition remains unclear. Studies to determine
this more precisely are of clinical and practical importance,
especially where they account for factors such as reduced physical
activity (PA), which are known to be associated with increased
anabolic resistance that cannot be reversed by increased
availability of AAs alone.26–28
The purpose of this study was to compare the efficacy of EAAs
enriched with different amounts of leucine on muscle mass and
physical performance in elderly men and women. We hypothe-
sised that an increase in the proportion of leucine in a modified
mixture of EAAs would be of greater benefit than a standard
mixture of EAAs or a placebo.
MATERIALS AND METHODS
Study design
This is a double-blinded randomised controlled pilot trial of the effects of
mixtures of EAAs in retired men and women. The study was approved by
the University Research Ethics Committee. Signed informed consent was
provided by all subjects before testing and intervention.
Subjects/Population
Thirty-six men (n=36) and women aged 65 to 75 years volunteered to take
part, and twenty-five (n=25) completed all pre- and post-functional and
body composition tests. None of them smoked, all were living
independently and were of good health. Of the initial number (n= 36),
those with lactose intolerance, vascular disease, hypertension, diabetes,
cardiac abnormalities and the presence of metabolic disease or injury were
excluded from participation (n= 3); others withdrew from the study
outlining either personal reasons or inability to take the supplements
(n=6), and data from two subjects were not included in the final analysis
because of non-compliance with the experimental protocol.
Protocol
Subjects received one of the following daily:
(A) Standard EAA mixture (20% leucine)
(B) Modified EAA mixture (40% leucine)
(C) Isocaloric placebo (lactose).
The supplementation period was 3 months and it was in accordance
with EWGSOP recommendations. Primary outcomes were total lean mass
and physical performance. Measurements were taken at baseline and
immediately post intervention. A standardised health screening and a pre-
exercise screening questionnaire, blood pressure, resting heart rate and
oxygen saturation levels were taken at each time point.
Supplements and diet
Supplements. Subjects ingested the isocaloric supplements in indistin-
guishable gelatine clear capsules (Size 00, CapsulCN) with breakfast and
dinner. As lean body mass was improved after daily ingestion of 15 g of
EAAs in sedentary elderly women,18 we made a decision to use the
equivalent relative amount (0.21 g /kg/day). Compliance was monitored by
recording the number of capsules that were not taken. The EAAs (Arndale
Ingredients, South Shields, UK) were packed into drums (Direct Food
Ingredients Ltd, Macllesfield, UK) and placed in capsules using a capsule
filler (CN-300, CapsulCN, Franklin Lakes, NJ, USA). The composition of the
EAA mixtures can be seen in Table 1. A decision was made not to reduce
the concentration of the branched chain AAs (BCAAs) isoleucine and valine
in the enriched mixture; high intakes of leucine may increase the oxidation
of isoleucine and valine and therefore limit their availability to synthesise
new protein, and reduced isoleucine availability may decrease leucine
transport into the cells.29–31 Therefore, we reduced only the percentage of
the remaining EAAs in the modified mixture. The amount of ingested
leucine remained below the upper tolerable and safe limit in humans of
0.53 g/kg/day,32 taking into account that the daily relative leucine intake in
the enriched mixture was 0.08 g/kg/day. In absolute terms, a person
weighing 80 kg would need to receive 16.8 g of EAAs on a daily basis, of
which 6.72 g would be in the form of leucine.
Diet. In week 1 of supplementation, subjects who completed the
intervention period (n= 25) recorded all food and drinks consumed over
a 3-day period. The process was repeated post intervention; however, 6
subjects failed to return their food diaries. Subjects received guidance on
recording food and drink by household measures and weight, and subjects
were asked to retain all packaging and food labels. Food diaries were
coded and dietary analysis was undertaken using NetWISP version 3.0
(Tinuviel Software, Warrington, UK). Macronutrient and alcohol intakes
were obtained, each expressed as the percentage of total energy intake.
Total energy intake was also expressed as a percentage of estimated
average requirements. Protein, iron, calcium and vitamin D were expressed
as a percentage of Reference Nutrient Intake.33 Protein was also calculated
in g/kg/day.
Body composition
Subjects were measured wearing light-weight clothing with jewellery
removed. Height was determined with a stadiometer (SECA, Birmingham,
UK), and body weight was recorded by electronic scales (SECA). Whole-
body composition was assessed using dual-energy X-ray absorptiometry
scan (Lunar iDXA, GE Healthcare, Madison, WI, USA) with calibration
checked daily using the GE Lunar calibration phantom. Precision for
measurements in our unit are 0.5%, 0.8% and 0.6% for lean tissue, fat and
bone mass, respectively.34
Functional performance (FP) testing and PA levels
Tests were delivered in the following order: 30-s arm-curl test, 30-s chair-
stand test (30-CST), handgrip strength test and 6-min walk test (6-WT).35
Techniques adopted have been described previously.35,36 For familiar-
isation purposes, subjects performed sub-maximum efforts before maximal
testing. Ratings of perceived exertion were recorded at the end of each
exercise and attempt.37 Neoprene dumbbells (5 and 8 lbs for women and
men, respectively) and a 44 -cm-height straight-back chair without arm
rests were used during the 30-s arm-curl test and the 30-CST, respectively.
A digital handheld dynamometer (Takei, Scientific Instruments Ltd, Niigata,
Japan) recorded isometric strength of the dominant arm with values
reported in the results section expressed relative to body weight (N/kg
bw). During the 6-WT, subjects walked their maximal distance (50 m,
20× 5m2 rectangle) in 6min.
A 7-day physical activity recall38 was used to estimate general PA levels.
Blood sampling and analysis
A sub-group (n= 5, n= 4, and n= 6 from groups A, B and C, respectively)
volunteered for measurement of plasma concentrations of BCAAs and the
non-essential AAs Alanine, Glycine and Proline. In an attempt to reduce
attrition, blood sampling was not compulsory; therefore, blood was drawn
from a convenience sample in each group. Subjects remained seated in a
reclined position for 5 min before 2ml of blood was drawn from one
of the brachial, medial cubital or radial veins. Samples were drawn into
3.5- ml fluoride oxalate BD vacutainer tubes (Becton Dickinson and
Company, Franklin Lakes, NJ, USA) and centrifuged for 10min at 3000
revolutions/minute (ALC multispeed centrifuge PK 131R, ALC, Milan, Italy).
Two aliquots of plasma were stored at − 80 °C. Before analysis, each sample
Table 1. Composition of essential amino-acid mixtures per 100 g
Amino acids Standard essential
amino-acid mixture
containing 20% leucine
Modified essential
amino-acid mixture
containing 40% leucine
Histidine 10 5
Isoleucine 11 11
Leucine 20 40
Lysine 15 12
Methionine 3 2
Phenylalanine 15 7
Threonine 14 11
Valine 12 12
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was thawed, an internal standard was added and proteins were removed
by ultrafiltration. The ultrafiltrate was acidified and the sample was
subjected to cation exchange clean-up, with elution in ammonium
hydroxide. Samples were dried down and derivatised for gas chromato-
graphy mass spectrometry analysis. Plasma AAs were analysed by gas
chromatography mass spectrometry after ultrafiltration, cation exchange
and derivatisation as ethoxycarbonyl ethyl esters. Nor-leucine was used as
an internal standard for quantification of the neutral AAs.
Statistics
SPSS statistical software was used for analysis (PASW 18, SPSS, Hong Kong,
China). Data are presented as means (± standard deviations). Normality
was assessed using the Shapiro–Wilk Test, and data violating homogeneity
assumptions were assessed via a Kruskal–Wallis test. One-way analysis of
variance (ANOVA) tested for differences at baseline and compared mean
percentage differences between groups A, B and C; significant interactions
were explored using the Holm–Bonferonni post-hoc adjustment. Repeated-
measures ANOVA was used test for body composition, FP, PA and RPE
main effects; paired t-tests were used for within-group comparisons
(baseline to post-intervention) when ANOVA resulted in significant main
effects or significant trends. For non-parametric data (including RPE), the
Wilcoxon signed rank test was used. Statistical comparisons for body
composition, FP variables and RPE were also performed using Cohen’s
Effect Size with threshold values for small (0.2), medium (0.6), large (1.2),
very large (2.0) and extremely large (4.0) effects. Statistical significance was
inferred as Po0.05.
RESULTS
Demographic data and body composition
The age and anthropometric characteristics are reported in
Table 2 and the body composition variables in Table 3.
Repeated-measures ANOVA revealed no time by participant
interaction effects (F(2,22) = 0.529, P= 0.596); however, main time
effects approached significance (F(1, 22) = 3.643, P= 0.069). Over
the 3 months, lean tissue mass (LTM) in Group B (modified EAA
(40% leucine)) increased significantly compared with baseline
(t(7) =−2.695, P= 0.031).
FP, PA and ratings of perceived exertion (RPE)
FP and average RPE ratings are given in Table 4. Significant
differences were not observed between groups in the mean
percentage changes in scores for the 30-s arm-curl test
(F(2,22) = 1.776, P= 0.193), the 30-CST (F(2,22) = 0.781, P= 0.470),
the handgrip strength test (F(2,22) = 1.271, P= 0.300) and the 6-WT
(F(2,22) = 2.225, P= 0.132). In contrast, mean percentage reduc-
tions in RPE were significant (F(2,22) = 4.683, P= 0.020); Group C
(Placebo) had the greatest reductions in RPE, which was
significantly different from Group A (P= 0.023).
The EAA groups demonstrated significant improvements in FP
compared with baseline. In Group A (standard EAA (20% leucine)),
improvements were observed in the 30-CST (t(7) =− 3.211,
P= 0.015)) and 6-WT (t(7) =− 2.859, P= 0.024)); in Group B
(modified EAA (40% leucine)), in the 6-WT (t(7) =− 2.659,
P= 0.032) and in the 30-CST, improvements almost reached
statistical significance (t(7) =− 2.173, P= 0.066). Baseline differ-
ences between Groups A (standard EAA (20% leucine)) and C
(placebo) in the 30-CST (F(2,22) = 6.3, P= 0.007) remained sig-
nificant at the end of the intervention (F(2,22) = 4.1, P= 0.03).
Mean improvements in FP tests in the EAA groups were also
associated with medium to large effect sizes (Table 4). No
additional effect size was noted for higher-dose leucine supple-
mentation (Group B) compared with standard dose (Group A) in
Table 2. Age and anthropometric characteristics of the subjectsa
Group Age (years) Height (m) Weight (kg) Body mass index (kg/m2)
Baseline 12 Weeks Baseline 12 Weeks
A
n= 8 (3 M, 5 F)
71.1± 2.7 1.68± 0.11 75.6± 15.3 76.7± 15.9 26.6± 3.8 26.8± 3.9
B
n= 8 (4 M, 4 F)
71.9± 3.0 1.67± 0.08 74.4± 12.7 74.8± 12.2 26.7± 3.4 26.8± 3.3
C
n= 9 (4 M, 5 F)
71.8± 2.7 1.64± 0.10 70.5± 12.4 70.8± 12.1 26.3± 3.9 26.4± 3.9
Average 71.6± 2.7 1.66± 0.09 73.4± 13.1 74.0± 13.1 26.5± 3.6 26.7± 3.6
F (2, 22) 0.169 0.425 0.332 0.426 0.024 0.166
P-value 0.846 0.659 0.721 0.658 0.976 0.848
Abbreviations: A, standard essential amino-acid mixture (containing 20% leucine); B, modified amino-acid mixture (containing 40% leucine); C, placebo;
F, female; M, male. aAll values are means± standard deviation.
Table 3. Assessment of body composition at baseline and at the end of the intervention perioda
Body composition variables Group A (n= 8) Group B (n=8) Group C (n=9)
Baseline Week 12 % ES Baseline Week 12 % ES Baseline Week 12 %
Total LTM (kg) 44.8± 7.1 44.8± 7.2 0.2± 2.4 − 0.4 45.5± 8.9 46.0± 9.1b 1.1± 1.1 0.2 42.6± 8.9 43.0± 9.3 0.8± 1.3
Total FM (kg) 27.8± 11.4 28.5± 11.2 4.3± 6.7 0.4 25.6± 6.2 25.7± 6.0 0.5± 2.6 − 0.2 24.9± 9.9 25.1± 9.7 1.5± 6.3
Percentage BF (%) 36.0± 10.5 36.7± 9.7 3.3± 6.1 0.5 34.8± 6.6 34.7± 6.5 − 0.4± 2.1 − 0.2 35.2± 11.2 35.2± 11.0 0.4± 4.7
Total BMC (kg) 2.6± 0.5 2.6± 0.5 0.1± 1.4 − 0.3 2.5± 0.6 2.5± 0.6 0.0± 1.0 − 0.4 2.4± 0.5 2.4± 0.5 0.4± 1.0
Total BMD (g/cm2) 1.1± 0.1 1.1± 0.1 0.2± 1.2 0.5 1.1± 0.2 1.1± 0.2 0.3± 1.6 0.5 1.1± 0.1 1.1± 0.1 − 0.4± 1.1
Abbreviations: A, standard essential amino-acid mixture (containing 20% leucine); B, modified amino-acid mixture (containing 40% leucine); C, placebo; BMC,
bone mineral content; BMD, bone mineral density; BF, body fat; ES, Effect Size; FM, fat mass; LTM, bone mineral-free lean tissue mass; %, mean percentage
change from baseline to week 12. aAll values are means± standard deviations. bDenotes significantly different from baseline value (Po0.05). ME=mean of the
experimental group, MP=mean of the placebo group. ES Cohen’s d= (ME-MP)/SD pooled).
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any of the FP tests (Table 4). RPE was reduced in Group C (placebo)
by the end of the intervention (Z=− 2.668, P= 0.008).
PA at baseline was similar across all groups, with the total
duration spent in activities being 7.4(±7.4), 8.97(±6.85) and 7.14
(±3.71) h for the A, B and C groups, respectively. Towards the end
of the intervention, Groups A, B and C increased on average their
total PA levels by 104.7(±344.3)%, 30.6(±107.2)% and 114.3
(±128.4)%, respectively. Mean percentage changes were not
significantly different between groups. However, Group C
(Placebo) increased total PA levels when compared with baseline
(t(8) =− 2.361, P= 0.046).
Nutrition
Percentage capsule intake was 75.0(±13.2)%, 75.8(±10.4)% and
85.8(±15.0)% for Groups A, B and C, respectively; however, it was
not significantly different between groups (P= 0.186). Energy
intakes were sub-optimal, although no significant differences
existed between groups (Table 5). Dietary protein intake (not
including EAA supplementation) ranged between 0.95 and1.10
and 1.02–1.08 g/kg/day at baseline and post-intervention, respec-
tively. The only difference observed was that Group C (placebo)
had greater % carbohydrate intake at baseline (46.9%) than both
EAA groups (Group A, 36.9%; Group B, 41.7%), and the lowest
alcohol intake, although not significantly different from the EAA
groups.
Blood data
Because of non-compliance and drop-out, n= 3 (Group A), n= 4
(Group B) and n= 6 (Group C) completed blood sampling. Plasma
AAs at baseline (Table 6) were similar, with the exception of
isoleucine and valine, which were significantly higher in Group B
(modified EAA (40% leucine)) than in Group C (placebo). Moreover,
isoleucine concentration in Group B was significantly higher than
in Group A (standard EAA (20% leucine)). There was a reduction
in the concentration of all AAs in Group B (modified EAA
(40% leucine)), no significant changes in Group A and only glycine
was significantly reduced in Group C (placebo). There were also
significant differences in the changes from pre- to post-
supplementation in isoleucine and valine. Post-hoc tests showed
that reductions in both AAs in Group B (modified EAA (40%
leucine)) were significantly different from the respective gains in
Groups A and C. No significant differences were observed
between Groups A and C.
Table 4. Assessment of functional performance and ratings of perceived exertion at baseline and at the end of the intervention perioda
Functional performance variables Group A (n= 8) Group B (n= 8) Group C (n = 9)
Baseline Week 12 % ES Baseline Week 12 % ES Baseline Week 12 %
30-ACT (no) 14.6± 4.7 16.3± 4.0 15.0± 20.0 0.8 17.4± 4.0 18.6± 3.6 8.3± 13.7 0.6 18.6± 3.0 18.7± 3.0 0.9± 11.2
30-CST (no) 11.6± 3.9b 12.8± 3.9b,c 11.0± 11.5 0.5 14.1± 2.0 15.9± 3.2 13.2± 16.0 0.5 16.4± 2.1 17.1± 2.3 4.7± 15.7
Relative HST (N/(kg.bw)) 2.8± 0.9 3.0± 1.0 11.5± 23.9 0.6 3.8± 1.2 3.9± 1.3 4.8± 7.5 0.6 4.0± 1.4 3.9± 1.3 − 0.2± 8.9
6-WT (m) 501.6± 101.1 539.0± 83.0c 8.8± 10.0 0.9 533.9± 81.0 562.1± 72.4c 5.8± 6.6 0.7 586.0± 85.0 593.0± 82.1 1.4± 4.5
Average RPE 11.3± 1.7 11.0± 1.5 − 2.0± 9.0b 1.3 11.7± 1.0 11.1± 1.6 − 5.2± 10.1 1.0 13.1± 1.6 11.3± 1.6c − 13.7± 5.1
Abbreviations: A, standard essential amino-acid mixture (EAAs); B, EAAs containing 40% leucine; C, placebo; ES, Effect Size; HST, handgrip strength test; no,
number of repetitions; RPE, rating of perceived exertion; %, mean percentage change from baseline to week 12; 30-CST, 30-s chair-stand test; 30-ACT, 30-s arm-
curl test; 6-WT, 6-min walk test. aAll values are means± standard deviations. bDenotes significantly different from placebo (Po0.05) ME= mean of the
experimental group, MP=mean of the placebo group. ES Cohen’s d = (ME-MP)/SD pooled). cDenotes significantly different from baseline value (Po0.05).
Table 5. Nutrient intakes at baseline and at the end of intervention
Nutritional variables Group A (n= 5) Group B (n= 8) Group C (n= 6) Pre- to post-
supplementation
difference across
groups (ANOVA)
Baseline Week 12 Mean
difference
Baseline Week 12 Mean
difference
Baseline Week 12 Mean
difference
P
Energy (kcal) 1872± 754 1811± 740 − 61± 325 1787± 305 1754± 363 − 33.0± 175 1845± 411 1812± 372 − 33.4± 325 0.96
Energy (Kcal) % EAR 97.4± 35.3 94.8± 33.0 − 2.6± 18.1 87.5± 13.0 85.7± 12.5 − 1.8± 8.3 89.0± 24.0 88.1± 20.8 − 0.9± 17.7 0.77
Total % fat 34.6± 12.3 28.2± 8.6 − 6.4± 7.3 32.7± 5.0 31.5± 2.3 − 1.2± 5.8 31.5± 5.2 32.3± 5.3 0.8± 6.5 0.98
Total % CHO 36.9± 6.9* 43.1± 3.1 6.2± 6.8* 41.7± 3.0 42.2± 8.2 0.5± 2.7 46.9± 6.0 47.8± 5.4 0.9± 3.3 0.05
Total % protein 14.1± 2.7 16.5± 4.7 2.4± 4.5 17.4± 3.8 18.2± 3.9 0.8± 5.5 16.9± 2.4 16.1± 3.1 − 0.8.± 2.6 0.34
Total % alcohol 14.3± 17.4 12.1± 13.6 − 1.8± 4.1 8.2± 6.1 8.2± 4.5 0± 4.7 4.7± 3.6 3.8± 4.3 − 0.9± 2.9 0.21
Protein (g) 62.5± 17.4 71.2± 30.2 8.7± 15.0 77.5± 18.4 72.3± 15.9 − 5.2± 16.7 77.8± 19.2 78.6± 20.2 0.8± 30.7 0.54
Protein(% RNI) 133.2± 37.9 152.2± 65.3 19.0± 32.2 166± 40.4 167± 44.1 1.8± 65.7 165.6± 39.1 150.1± 40.8 − 15.6± 39.8 0.57
Calcium (% RNI) 121± 65.4 108± 65.3 − 13.0± 28.6 109± 42.4 107.7± 31.7 − 1.3± 44.3 130± 42.0 121± 41.1 − 9.± 23.0 0.80
Iron (% RNI) 123.6± 65.0 123.2± 103.7 0.4± 73.2 98.6± 1.2 96.3± 35.0 − 2.3.± 43.0 116± 34.5 110± 43.7 − 6.0± 28.6 0.97
Vitamin D (% RNI) 20.6± 19.4 39.8± 64.0 19.2± 68.2 13.7± 5.5 46± 51.2 32.3± 50.8 34.5± 14.0 29.5± 19.5 − 5.± 29.7 0.34
Abbreviations: ANOVA, analysis of variance; A, standard essential amino-acid mixture (containing 20% leucine); B, modified amino-acid mixture (containing
40% leucine); C, placebo; EAR, estimated average requirement; RNI, reference nutrient intake. All values are means± standard deviation. Intakes were
calculated according to the following UK reference values EAR Energy= 2330 kcal/day ( male 65–74 years), 2100 kcal/day (male 75+ years), 1900 kcal/day
(female 65–74 years) and 1810 kcal/day (female 75+ years); RNI protein= 53.3 g/day (male 50+ years) and 46.5 g/day (female 50+ years); calcium= 700mg/day
(male and female 50+ years); iron= 8.7 mg/day (male and female 50+ years) and vitamin D= 10 μg/day (male and female 50+ years). *Denotes significantly
different from placebo (*Po0.05).
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DISCUSSION
As the first to investigate the comparative impact of two different
doses of leucine enriched amino-acid mixtures in healthy older
individuals, we report that the addition of standard (20%) and
high level (40%) leucine supplements appears to significantly
improve aspects of functional status, and at the higher level of
40% leucine, increases LTM.
Long-term supplementation studies examining the effective-
ness of leucine and EAAs enriched with leucine for prevention of
either age-related sarcopenia18,19 or enhancement of LTM20 are
few and remain equivocal. High-dose long-term leucine supple-
mentation alone taken as 7.5 g of free leucine rather than as part
of a mixed amino-acid mixture or meal has shown no benefit over
placebo, with both groups increasing LTM by ~ 0.4 kg.19 This
contrasts with the use of leucine-enriched AAs16,18,22 or the use of
a whey protein, leucine-enriched supplement, which has demon-
strated beneficial acute effects on muscle PS, and particularly at
higher concentrations of 40%. Similarly, animal studies have also
revealed that the amount of leucine required to maintain
postprandial stimulation of PS may be higher in older animals.23
In our study, PS was not measured; however, we can speculate
that the significant increase in LTM of subjects in Group B was
probably because of enhanced rates of PS as a result of an
increased leucine dose (leucine intake ~ 6 g/day) and in the
presence of other EAAs.
The increase of 1.1% in LTM (Leucine 40%) was lower than a
3.9% improvement achieved with an 18.6% leucine-enriched
amino-acid mixture administered to elderly sedentary women.18
Interestingly, Dillon et al.18 took no account of protein intakes at
baseline, with the potential that this was lower than our study,
with resultant greater gains in LTM at lower leucine concentra-
tions. Our subjects also received EAA amounts relative to their
body weight and not absolute amounts, which potentially may be
more beneficial for subjects with low body weight. Moreover, and
despite the fact that subjects in the study by Dillon et al.18 were
instructed to refrain from making any drastic changes to their
habitual PA levels, it is not guaranteed that this was the case;
subjects in our study were given similar instructions, but subjects
in the placebo group significantly increased their PA levels
compared with baseline. Dillon et al.18 on the other hand did not
report PA level data to confirm or refute their assumption that
subjects maintained their normal activity levels throughout the
3-month supplementation period. Bearing also in mind that
subjects in our EAAs groups managed only ~ 75% of the
prescribed dosage, it is highly probable that LTM gains were
sub-optimum when compared with the previous study.18 PA and
habitual protein intake may contribute to a blunted muscle
synthesis response to leucine supplementation.28,39 When total
dietary protein and leucine intakes are optimal, this may already
be sufficient to maximise muscle protein synthetic response;
therefore, additional supplementation may not be of any
benefit.19 It is possible that in the context of our subjects'
relatively high baseline protein intakes, only high-dose leucine23
or high-quality protein40 would positively have an impact on LTM.
Certainly, our subjects were well nourished. Dietary protein
(%RNI) exceeded that of UK and European adult population
recommendation41,42 and at intakes of 1–1.1 g/kg/day it just met
the proposed higher intakes of 1–1.5 g/kg/day for the prevention
of sarcopenia,8 implying that those in the EAA groups would
hypothetically require the very highest upper level of 1.5 g/kg/day
dietary protein in order to achieve benefit. Age-related issues
associated with consumption of food11,12 render achievement of
this high protein intake unlikely. Even if this were achieved, the
provision of extra protein may diminish the impact because of the
potential of protein to enhance satiety and subsequently reduce
energy intake.43 Although the standard EAA Group (20% leucine)
received as much protein and EAAs as those receiving the
modified EAA (40% leucine) supplement, the changes in LTM were
trivial, suggesting that the percentage concentration of AAs in the
20% supplement was not optimised for muscle growth. Surpris-
ingly, in the placebo group a small (0.8%) but non-significant
increase in LTM was not accompanied by significant gains in FP.
The potential reason for this discrepancy may be explained by the
placebo group significantly increasing their PA levels, which was
also associated with reduced RPE levels, compared with baseline,
and in so doing, stimulated the known anabolic role of exercise44
and increased the utilisation of AAs for muscle PS through
increased blood flow.45 Compliance to intervention is a major
challenge in research of this nature, as demonstrated by our study.
Despite the fact that LTM gains were lower than previously
reported18 for a standard mixture of EAAs, our data showed a
significant trend for greater gains in LTM when subjects were
supplemented with a modified mixture enriched with leucine,
which was not the case for a standard mixture and a placebo. Our
study also highlighted that PA in particular is a confounding factor
that can contribute to LTM gains. Therefore, it is recommended
that future studies include regular monitoring and encourage-
ment of trial conditions during the intervention duration. More
specifically, there is a need for incorporating direct measures of PA
levels such as accelerometers46,47 rather than just relying on self-
reported tools such as the 7-day recall, which may reasonably
assess total and very hard PA levels in men; however, it is less
accurate in women and when the majority of activities are light or
moderate.48
The presentation of leucine appears to have a key role in its
action. Increasing age results in an uncoupling of the regulatory
Table 6. Concentration of amino acids (μMol/l) at baseline and at the end of intervention
Amino
acids
Group A (n= 3) Group B (n= 4) Group C (n= 6) Pre to post
supplementation
difference across groups
(ANOVA)
Baseline Week 12 Mean
difference
Baseline Week 12 Mean
difference
Baseline Week 12 Mean
difference
P
Leucine 147.3± 8.1 175.3± 24.6 28.0± 29.1 224.0± 82.5 187.0± 21.5 − 37.0± 75.3 142.5± 36.4 145.8± 23.0 3.3± 33.3 0.250
Isoleucine 64.7± 7.6 78.7± 6.0 14.0± 14.0 101.7± 24.0a,b 65.3± 9.6c − 36.5± 15.4 61.7± 10.8 66.2± 11.4 4.5± 14.7 0.002
Valine 192.0± 23.6 219.7± 43.7 27.7± 46.1 259.5± 41.5a 203.8± 39.7c − 55.8± 27.6 175.8± 42.1 198.5± 37.0 22.7± 39.3 0.017
Alanine 223.0± 93.2 250.7± 84.8 27.7± 84.2 254.5± 47.7 212.3± 54.4c − 42.3± 23.0 241.3± 46.1 259.7± 39.1 18.3± 33.8 0.119
Glycine 180.0± 51.6 172.7± 110.0 − 7.3± 59.1 186.0± 31.4 156.3± 17.9c − 29.8± 18.5 193.2± 73.1 223.5± 96.7c 30.3± 28.1 0.059
Proline 141.0± 33.9 140.3± 5.8 − 0.7± 39.0 132.5± 12.7 114.8± 22.9 − 17.8± 26.0 112.5± 26.8 128.0± 40.0 15.5± 32.2 0.310
All values are means± standard deviation. Abbreviations: ANOVA, analysis of variance; A, standard essential amino-acid mixture (EAAs); B, EAAs containing
40% leucine; C, placebo. aDenotes significantly different from placebo (Po0.05). bDenotes significantly different from group A (Po0.05) cDenotes significantly
different from baseline value (Po0.05).
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mechanism for protein balance and a reduced ability to use
dietary protein.17 In younger populations, a standard mixture of
EAAs was shown to be as effective in stimulating muscle PS as
an EAA mixture enriched with leucine (35%), although the
higher leucine concentration also decreased muscle protein
breakdown rate.31 A higher arterial leucine concentration did
not result in increased leucine transport or intracellular availability,
as the decrease in isoleucine may have been the limiting factor for
leucine transport in the cell. In the majority of studies in which a
mixture of EAAs was enriched with leucine, the concentration of
the other BCAAs was reduced, potentially rendering the EAA
mixture sub-optimal. In contrast, we maintained the relative
proportion of isoleucine and valine as in a standard mixture, and
administered alongside food. Our data suggest that increased
dosage of leucine, BCAAs and EAAs through supplementation and
food can benefit the functional status and body composition of
elderly men and women. It is noteworthy that % alcohol intake
was two or three times greater in the EAA groups than in the
placebo. Alcohol has been shown to inhibit the ability of leucine
to increase PS49,50 and may have blunted the effects of leucine on
accrual of LTM. Assuming that alcohol intake was similar in all
groups, we would expect to observe greater gains in LTM of the
EAA groups compared with the placebo. Concentrations of
isoleucine and valine were significantly decreased at the end of
the intervention, which is in agreement with other studies,51–53
although we cannot confirm whether this change was because of
decreased rates in protein breakdown or increase in PS rates. In
rats fed a BCAA mixture enriched with leucine (31%), a greater life
span and increased mitochondrial synthesis in cardiac and skeletal
muscle have been noted.23 This supports an additional benefit of
leucine and/or EAA supplementation other than LTM gains alone.
Certainly, there were significant performance gains in Group A
(standard EAA (20% leucine)) that may potentially be influenced
by changes at the mitochondrial level and is worthy of further
investigation.
In contrast to other studies, subjects in the EAA groups improved
FP, suggesting that supplementation with EAAs is an effective
nutritional therapy for age-related sarcopenia with or without the
presence of exercise,54 which is a known enhancer of effect. Studies
of similar duration18,19 indicate no impact of EAAs or leucine
supplementation on strength. This is of no surprise, as subjects did
not take part in a resistance exercise training intervention and the
strength tests assessed one-repetition maximum strength rather
than FP. In terms of bone health, our findings also suggest that
supplementation with EAAs may improve bone mineral density, as
there was an increase in bone mineral density, which was supported
by medium effect sizes (0.5) for both the 20 and 40% groups,
whereas this was not the case for the placebo group. Three months
is a short duration over which to assess change in bone density
owing to bone remodelling cycle dynamics; therefore, research over
6 months is required to further explore this potential.
Although the findings above lend support to continued use of
our own leucine-enriched formulation in the longer term, there is
a need for further research with larger sample sizes before
concrete recommendations are made. Moreover, adherence rates
of 74–83% suggest that supplement presentation and palatability
require further evaluation and development. The high attrition
rates (30%) and the reasons subjects outlined for their withdrawal,
also lend further support to the need for further development of
nutritional products that deliver EAAs in a more compact,
palatable and acceptable way to an elderly population.
CONCLUSION AND RECOMMENDATIONS
Our data support the potential prophylactic role of EAAs and in
particular leucine and BCAAs for the treatment of sarcopenia.
Twice-daily supplementation with 0.21 g/kg/day EAAs (modified
EAA (leucine 40%)) alongside a diet providing adequate protein
and energy resulted in significant gains in FP and LTM, which was
not the case for the placebo. On the other hand, the standard
mixture of EAAs (leucine 20%) was associated with FP gains in the
absence of changes in LTM. Our findings support the higher
protein recommendations proposed for older individuals. Further
studies examining the impact of higher dietary protein intakes on
diagnostic criteria of sarcopenia such as physical performance and
LTM are required, as well as studies on how palatability and satiety
might also be addressed.
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